作者
Deepankar K Sinha, Adithya Balasubramanian, Alexander J Tatem, Jorge Rivera-Mirabal, Justin Yu, Jason Kovac, Alexander W Pastuszak, Larry I Lipshultz
发表日期
2020/3
来源
Translational andrology and urology
卷号
9
期号
Suppl 2
页码范围
S149
出版商
AME Publications
简介
Male hypogonadism is an increasingly prevalent clinical condition that affects patients’ quality of life and overall health. Obesity and metabolic syndrome can both cause and result from hypogonadism. Although testosterone remains the gold standard for hypogonadism management, its benefits are not always conserved across different populations, especially with regards to changes in body composition. Partially in response to this, growth hormone secretagogues (GHS) have emerged as a potential novel adjunctive therapy for some of the symptoms of hypogonadism, although current data on their clinical efficacy largely remain lacking. The present review examines the existing literature on the use of GHS and explores their potential complementary role in the management of hypogonadal and eugonadal males with metabolic syndrome or subclinical hypogonadism (SH). The GHS that will be discussed include …
学术搜索中的文章
DK Sinha, A Balasubramanian, AJ Tatem… - Translational andrology and urology, 2020